程序性死亡受体1抑制剂联合化疗一线治疗程序性死亡受体配体1高表达晚期非小细胞肺癌患者的疗效分析  

Efficacy analysis of programmed death-1 inhibitor combined with chemotherapy as first-line treatments in advanced non-small cell lung cancer with high programmed death-ligand 1 expression

作　　者：陈思远 秦玉慧 杜志娟 李亚男 吕雅晖 杜翔宇 刘哲峰 Chen Siyuan;Qin Yuhui;Du Zhijuan;Li Yanan;Lyu Yahui;Du Xiangyu;Liu Zhefeng(Department of Oncology,The First Medical Center,Chinese PLA General Hospital,Beijing 100853,China;Department of Medical Oncology,Senior Department of Oncology,The Fifth Medical Center of PLA General Hospital,Beijing 100853,China)

机构地区：[1]中国人民解放军总医院第一医学中心肿瘤科,北京100853 [2]中国人民解放军总医院第五医学中心肿瘤医学部肿瘤内科,北京100853

出　　处：《肿瘤综合治疗电子杂志》2025年第1期124-129,共6页Journal of Multidisciplinary Cancer Management(Electronic Version)

摘　　要：目的探究程序性死亡受体1(programmed death-1,PD-1)抑制剂联合化疗一线治疗程序性死亡受体配体1(programmed death-ligand 1,PD-L1)高表达[PD-L1肿瘤细胞阳性比例分数(tumor proportion score,TPS)≥50%]晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的疗效。方法回顾性分析2018年9月至2023年4月于中国人民解放军总医院第一医学中心接受PD-1抑制剂单药或PD-1抑制剂联合化疗一线治疗的PD-L1高表达晚期NSCLC患者的临床资料和治疗反应,并随访生存情况。主要研究终点为中位无进展生存(median progression-free survival,mPFS)时间和中位总生存(median overall survival,mOS)时间,次要研究终点为疾病控制率(disease control rate,DCR)和客观缓解率(objective response rate,ORR)。比较PD-1抑制剂单药(PD-1抑制剂单药组)与PD-1抑制剂联合化疗(PD-1抑制剂联合化疗组)一线治疗PD-L1高表达晚期NSCLC患者的疗效。结果共收集PD-L1高表达晚期NSCLC患者132例,其中PD-1抑制剂单药组42例,PD-1抑制剂联合化疗组90例。PD-1抑制剂单药组与PD-1抑制剂联合化疗组的mPFS时间(20.3个月∶18.4个月,P=0.594)和mOS时间(33.9个月∶51.1个月,P=0.640)比较差异均无统计学意义。PD-1抑制剂单药组的ORR(47.6%∶68.9%,P=0.019)和DCR(90.5%∶98.9%,P=0.035)均显著低于PD-1抑制剂联合化疗组。结论PD-1抑制剂单药与PD-1抑制剂联合化疗一线治疗PD-L1高表达晚期NSCLC患者的长期疗效相当,但PD-1抑制剂联合化疗的短期疗效优于PD-1抑制剂单药。Objective To investigate the of efficacy programmed death-1(PD-1)combined with chemotherapy as first-line treatments in advanced non-small cell lung cancer(NSCLC)with high programmed death-ligand 1(PD-L1)expression[tumor proportion score(TPS)≥50%].Method Retros-pective analysis of clinical data and treatment response of PD-L1 overexpression advanced NSCLC patients who received first-line treatment of PD-1 inhibitor monotherapy or PD-1 inhibitor combined with chemotherapy in the First Fifth Medical Center,Chinese PLA General Hospital from September 2018 to April 2023,and follow-up of survival.The main research endpoint endpoints of the study were median progression-free survival(mPFS)time and median overall survival(mOS)time,while the secondary endpoints were disease control rate(DCR)and objective response rate(ORR).The efficacy of PD-1 inhibitor monotherapy(PD-1 inhibitor monotherapy group)and PD-1 inhibitor combined chemotherapy(PD-1 inhibitor combination chemotherapy group)infirst-line treatment of advanced NSCLC patients with high PD-L1 expression was compared.Result A total of 132 patients with advanced NSCLC with high expression of PD-L1 were collected,including 42 patients in the PD-1 inhibitor monotherapy group and 90 patients in the PD-1 inhibitor combined with chemotherapy group.There were no significant differences in mPFS time(20.3 months∶18.4 months,P=0.594)and mOS time(33.9 months∶51.1 months,P=0.640)between PD-1 inhibitor monotherapy group and PD-1 inhibitor combined with chemotherapy group.The ORR(47.6%∶68.9%,P=0.019)and DCR(90.5%∶98.9%,P=0.035)of PD-1 inhibitor monotherapy group were significantly lower than those of PD-1 inhibitor combined with chemotherapy group.Conclusion PD-1 inhibitor monotherapy and PD-1 inhibitor combined with chemotherapy showed no significant differences in long-term efficacy infirst-line treatment of advanced NSCLC with high PD-L1 expression.However,PD-1 inhibitor combined with chemotherapy demonstrated superior short-term efficacy compared to PD-1 inhibitor mo

关 键 词：非小细胞肺癌 程序性死亡受体1 程序性死亡受体配体1 免疫治疗 化疗 

分 类 号：R73[医药卫生—肿瘤]